204 related articles for article (PubMed ID: 18765687)
1. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
3. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
4. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
5. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
6. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
8. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
Weiner M; Burman W; Luo CC; Peloquin CA; Engle M; Goldberg S; Agarwal V; Vernon A
Antimicrob Agents Chemother; 2007 Aug; 51(8):2861-6. PubMed ID: 17517835
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
10. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
11. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
[TBL] [Abstract][Full Text] [Related]
13. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
[TBL] [Abstract][Full Text] [Related]
14. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A; Eller MG; McKenzie KA; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
[TBL] [Abstract][Full Text] [Related]
15. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
16. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.
Weiner M; Egelund EF; Engle M; Kiser M; Prihoda TJ; Gelfond JA; Mac Kenzie W; Peloquin CA
J Antimicrob Chemother; 2014 Apr; 69(4):1079-85. PubMed ID: 24343893
[TBL] [Abstract][Full Text] [Related]
18. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of rifapentine in elderly men.
Keung AC; Eller MG; Weir SJ
Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
